Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InspireMD (NSPR) Cash & Equivalents (2016 - 2025)

InspireMD (NSPR) has 16 years of Cash & Equivalents data on record, last reported at $63.4 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 300.83% year-over-year to $63.4 million; the TTM value through Sep 2025 reached $63.4 million, up 300.83%, while the annual FY2024 figure was $18.9 million, 96.22% up from the prior year.
  • Cash & Equivalents reached $63.4 million in Q3 2025 per NSPR's latest filing, up from $11.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $63.4 million in Q3 2025 and bottomed at $3.9 million in Q3 2022.
  • Average Cash & Equivalents over 5 years is $17.5 million, with a median of $12.0 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 1301.91% in 2021, then crashed 84.57% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $12.0 million in 2021, then crashed by 61.41% to $4.6 million in 2022, then surged by 108.12% to $9.6 million in 2023, then soared by 96.22% to $18.9 million in 2024, then surged by 235.18% to $63.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $63.4 million in Q3 2025, $11.5 million in Q2 2025, and $12.4 million in Q1 2025.